Global Contract Manufacturing/ Contract Development And Manufacturing Organization (CMO/ CDMO) Market To Surpass US$ 18 Bn By 2020

An increasing number of companies within the pharmaceutical sector have been considering contract manufacturing in response to the increasing demand for generic drugs and biologics. In a new study, Future Market Insights (FMI) has forecast the global contract manufacturing/ contract development and manufacturing organization (CMO/ CDMO) market to surpass US$ 18 Bn by 2020.

Get | Download Sample Copy with Graphs & List of Figures:
https://www.futuremarketinsights.com/reports/sample/rep-gb-13038

According to the study, contract manufacturing accounts for 3/4th of all the CMO and CDMO services. Focus towards cost management, enhanced process flow, and better scalability will drive the market over the forecast period. Besides this, the increasing demand for skin care products, which also accounts for the leading share in terms of product type, will enable the market gain impetus in the coming years.

Currently an increasing number of consumers are shifting towards locally sourced and natural products rather than big brands. Achieving this will require state-of the-art technology besides other resources. As a result an increasing number of pharmaceutical companies are seeking services of contract manufacturing / contract development and manufacturing organization (CMO/CDMO).

Ask Us Your Questions About This Report:
https://www.futuremarketinsights.com/ask-question/rep-gb-13038

Key Takeaways from CMO/CDMOs Market Study

  • CMO/ CDMO services has become highly sought-after in pharmaceutical and beauty industries. FMI has projected the market to report 6.2% CAGR between 2020 and 2030
  • The U.S. is expected to account for over 77% of sales in North America by 2030
  • The U.K. will represent impressive scope for expansion, exhibiting above 7% CAGR through the forecast period
  • The rising focus on healthcare and wellness spending will support growth in Germany and France
  • The availability of inexpensive labor and resources will continue supporting growth in China. However, Japan and South Korea markets are expected to register higher percentage of growth over the forecast period

“Manufacturers operating in the market are keen on forging strategic partnerships with leading cosmetics brands and pharmaceutical companies. Collaborations are expected to remain a primary strategy adopted by market players to gain competitive edge,” says FMI analyst

In terms of the effect of COVID-19 pandemic on the demand of CMO/CDMO services, there was a negative impact on the market growth. One of the major issues was related to the supply chain gap. Prior to COVID-19, contract manufacturing was one of the most preferred sectors in the growing beauty and personal care industry. However, due to the pandemic, the industry suffered major setbacks as expected product launches were delayed. A shift was observed in consumer habits. Reduction of sales of leading products was recorded along with production slowdowns, which caused overhead to curb the profitability.

For More Information or Query or Customization Before Buying, Visit:
https://www.futuremarketinsights.com/customization-available/rep-gb-13038

Who is Winning?

Collaboration is the key strategy amongst market players. The CMO/CDMO companies continue to focus on collaborations to gain sustainability in the market.

  • For instance, In February 2021, Lonza signed an agreement to divest its specialty ingredients business to Bain Capital and Cinven, aiming to refocus as a pure-play partner to the healthcare industry.
  • In 2021, Pierre Fabre Group hosted a pioneering custom online partnering forum, partnering with biopharmaceutical firms aiming to accelerate the digital transformation of Pierre Fabre Group
  • In 2020, In March 2020, Pierre Fabre Group, in partnership with numerous hospitals in the Occitania region of France, donated hand care creams, body cleansing gels and thermal spring water sprays and hand sanitizers necessary to combat the spread of Covid-19.

Leave a comment

Your email address will not be published.